News Feed Item

Molecular Medicine Awards 2nd Annual Ross Prize to NIH Scientist Dr. John O'Shea

Celebration and symposium to be held in New York on June 9

MANHASSET, N.Y., April 23, 2014 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research today announced that John J. O'Shea, MD, scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (NIH), will be the recipient of the second annual Ross Prize in Molecular Medicine. The Ross Prize is issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine. The Prize, which includes a $50,000 gift, will be formally presented to Dr. O'Shea on June 9 at the New York Academy of Sciences in Manhattan, followed by an academic lecture by Dr. O'Shea and several other preeminent researchers.

The Ross Prize is made possible by the generosity of Feinstein Institute board members Robin and Jack Ross of Upper Brookville, NY. It is awarded annually by Molecular Medicine to mid-career scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

"John O'Shea turned his passion for clinical care into a successful research career pushing the frontiers of molecular medicine," said Feinstein Institute President, Kevin J. Tracey, MD, who also serves as editor-in-chief of Molecular Medicine. "His dedication and focus on the cytokine field have led to new treatments for immune diseases."

"It is very humbling to be awarded the 2014 Ross Prize in Molecular Medicine," said Dr. O'Shea. "From the beginning of my career, I was hoping to make discoveries that are important scientifically, but also directly help people – for me, it doesn't really get any better than that. It is very gratifying that my efforts to these ends are being recognized by this award."

On June 9, at a ceremony to be held at the New York Academy of Sciences in Manhattan, Dr. O'Shea will be presented the Ross Prize. After the award presentation, Dr. O'Shea; James P. Allison, PhD, The University of Texas MD Anderson Cancer Center; Louis M. Staudt, MD, PhD, National Cancer Institute, NIH; and Charles A. Dinarello, MD, University of Colorado at Denver, will each present scientific lectures. These preeminent researchers will discuss the mechanisms of immune system function and signaling, which may improve the treatment for cancer and various autoimmune diseases. To learn more about and register for the Ross Prize celebration and symposium, visit www.nyas.org/RossPrize2014. Registration is free.

Dr. O'Shea has been a physician and immunologist at NIH for 33 years. He has made fundamental discoveries related to the signaling of cytokines – molecules that are critical for the development and functioning of the immune system. His research also has focused on the molecular cause of primary immunodeficiencies, inherited conditions in which immune function is impaired, and the genetic basis of autoinflammatory disorders, conditions in which the body attacks its own tissues. He was awarded a US patent for his work on Janus family kinase inhibitors as a new class of immunosuppressive drugs. Dr. O'Shea developed a Cooperative Research and Development Agreement with the pharmaceutical company Pfizer, which generated one such compound that is approved for the treatment of rheumatoid arthritis. 

Dr. O'Shea graduated Phi Beta Kappa from St. Lawrence University, Canton, NY, and received his medical degree from the University of Cincinnati. After completing his residency in internal medicine at the State University of New York Upstate Medical University, Syracuse, he received subspecialty training in allergy and immunology at NIH. He was appointed chief of the NIAMS Molecular Immunology and Inflammation Branch in 2002, and became scientific director of the NIAMS Intramural Research Program in 2005. Dr. O'Shea has been the recipient of numerous awards and is a Fellow of the American Association for the Advancement of Science.

For the Ross Prize, Dr. O'Shea was selected by an awards committee comprised of:

  • Christopher J. Czura, PhD, vice president, scientific affairs, and executive editor, Molecular Medicine, Feinstein Institute for Medical Research;
  • Betty Diamond, MD, head, Center for Autoimmune Diseases and Musculoskeletal Disorders, Feinstein Institute;
  • Peter K. Gregersen, MD, head, Laboratory of Genomics and Human Genetics, Feinstein Institute;
  • Göran K. Hansson, MD, PhD, professor of experimental cardiovascular research, Karolinska Institute, Sweden;
  • Klas Kärre, MD, PhD, professor of molecular immunology, Karolinska Institute; and
  • Kevin J. Tracey, MD, president, Feinstein Institute.

About Molecular Medicine
Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by The Feinstein Institute for Medical Research. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, go to www.molmed.org.

About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit www.FeinsteinInstitute.org.

SOURCE The Feinstein Institute for Medical Research

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
So you think you are a DevOps warrior, huh? Put your money (not really, it’s free) where your metrics are and prove it by taking The Ultimate DevOps Geek Quiz Challenge, sponsored by DevOps Summit. Battle through the set of tough questions created by industry thought leaders to earn your bragging rights and win some cool prizes.
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
The Internet of Things (IoT), in all its myriad manifestations, has great potential. Much of that potential comes from the evolving data management and analytic (DMA) technologies and processes that allow us to gain insight from all of the IoT data that can be generated and gathered. This potential may never be met as those data sets are tied to specific industry verticals and single markets, with no clear way to use IoT data and sensor analytics to fulfill the hype being given the IoT today.
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive the discussion. According to Onalytica the "analysis showed a very engaged community with a lot of interactive tweets. The M2M discussion seems to be more fragmented and driven by some of the major brands present in the...
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
SYS-CON Events announced today that SoftNet Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. SoftNet Solutions specializes in Enterprise Solutions for Hadoop and Big Data. It offers customers the most open, robust, and value-conscious portfolio of solutions, services, and tools for the shortest route to success with Big Data. The unique differentiator is the ability to architect and ...
DevOps is speeding towards the IT world like a freight train and the hype around it is deafening. There is no reason to be afraid of this change as it is the natural reaction to the agile movement that revolutionized development just a few years ago. By definition, DevOps is the natural alignment of IT performance to business profitability. The relevance of this has yet to be quantified but it has been suggested that the route to the CEO’s chair will come from the IT leaders that successfully ma...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
In the next forty months – just over three years – businesses will undergo extraordinary changes. The exponential growth of digitization and machine learning will see a step function change in how businesses create value, satisfy customers, and outperform their competition. In the next forty months companies will take the actions that will see them get to the next level of the game called Capitalism. Or they won’t – game over. The winners of today and tomorrow think differently, follow different...
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will advance interoperability between connected devices from both groups, enabling the full operating potential of IoT and representing a significant step towards a connected ecosystem.
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...